Intolerability of cobalt salt as erythropoietic agent

Drug Testing and Analysis

Volumn 6, Issue 3, 2014, Pages 185-189

  Ebert, Bastian ^a   Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anaemia therapy; Cobalt; Doping; Erythropoiesis; Erythropoietin

Indexed keywords

CHLORINE COMPOUNDS; HEALTH RISKS; TRANSCRIPTION;

ANEMIA THERAPY; COBALT ION; COBALT SALTS; CRITICAL FACTORS; ERYTHROPOIESIS; ERYTHROPOIETIN; HAEMOGLOBINS; HYPOXIA-INDUCIBLE TRANSCRIPTION FACTORS; ORALLY ACTIVE; RISKS TO HEALTH;

COBALT COMPOUNDS;

COBALT CHLORIDE; COBALT DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ATHLETE; COBALT THERAPY; DIGESTIVE SYSTEM INJURY; DRUG SAFETY; DRUG TOLERANCE; ERYTHROPOIESIS; HEART INJURY; HUMAN; MEDICAL LITERATURE; MEDLINE; NERVE INJURY; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SYSTEMATIC REVIEW; THYROID DISEASE; TREATMENT OUTCOME;

ANAEMIA THERAPY; COBALT; DOPING; ERYTHROPOIESIS; ERYTHROPOIETIN;

ANEMIA; ANIMALS; COBALT; ERYTHROPOIESIS; HEMATINICS; HUMANS;

EID: 84896403918     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1528     Document Type: Review

References (67)

1. W. Jelkmann. Erythropoiesis stimulating agents and techniques: A challenge for doping analysts. Curr. Med. Chem. 2009, 16, 1236.
2. W. Jelkmann, C. Lundby. Blood doping and its detection. Blood 2011, 118, 2395.
3. C. Reichel, G. Gmeiner. Erythropoietin and analogs. Handb. Exp. Pharmacol. 2010, 195, 251.
4. M. Okano, M. Sato, E. Kaneko, S. Kageyama. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application. Drug Test. Anal. 2011, 3, 798.
5. S. Beuck, W. Schanzer, M. Thevis. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test. Anal. 2012, 4, 830.
6. W. Jelkmann. The disparate roles of cobalt in erythropoiesis, and doping relevance. Open J. Hematol. 2012, 3, 1.
7. F. J. Rodriguez-Jimenez, V. Moreno-Manzano. Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective. Cell. Mol. Life Sci. 2012, 69, 519.
8. E. Goldwasser, L. O. Jacobson, W. Fried, L. F. Plzak. Studies on erythropoiesis V. The effect of cobalt on the production of erythropoietin. Blood 1958, 13, 55.
9. W. Jelkmann. Efficacy of recombinant erythropoietins: Is there unity of international units? Nephrol. Dial. Transpl. 2009, 24, 1366.
10. L. Weißbecker. Die Kobalttherapie. Dtsch. Med. Wochenschr. 1950, 75, 116.
11. J. E. Davis, J. P. Fields. Experimental production of polycythemia in humans by administration of cobalt chloride. Proc. Soc. Exp. Biol. Med. 1958, 99, 493.
12. J. C. Robinson, G. W. James III, R. M. Kark. The effect of oral therapy with cobaltous chloride on the blood of patients suffering with chronic suppurative infection. New Engl. J. Med. 1949, 240, 749.
13. G. Lippi, M. Franchini, G. C. Guidi. Blood doping by cobalt. Should we measure cobalt in athletes? J. Occup. Med. Toxicol. 2006, 1, 18.
14. T. Smith, C. J. Edmonds, C. F. Barnaby. Absorption and retention of cobalt in man by whole-body counting. Health Phys. 1972, 22, 359.
15. J. M. Christensen, O. M. Poulsen, M. Thomsen. A short-term cross-over study on oral administration of soluble and insoluble cobalt compounds: Sex differences in biological levels. Int. Arch. Occup. Environ. Health 1993, 65, 233.
16. J. Edel, G. Pozzi, E. Sabbioni, R. Pietra, S. Devos. Metabolic and toxicological studies on cobalt. Sci. Total Environ. 1994, 150, 233.
17. WHO International Agency for Research on Cancer Working Group. Cobalt in hard metals and cobalt sulfate, gallium arsenide, indium phosphide and vanadium pentoxide. IARC Monogr. Eval. Carcinog. Risks Hum. 2006, 86, 1. Available at: http://monographs.iarc.fr/ENG/Monographs/vol86/mono86.pdf Access date: [16 August 2013].
18. J. A. Jefferson, E. Escudero, M. E. Hurtado, J. Pando, R. Tapia, E. R. Swenson, J. Prchal, G. F. Schreiner, R. B. Schoene, A. Hurtado, R. J. Johnson. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet 2002, 359, 407.
19. A. K. Nandedkar, M. S. Hong, F. Friedberg. Co2+ binding by plasma albumin. Biochem. Med. 1974, 9, 177.
20. H. M. Jansen, S. Knollema, L. V. van der Duin, A. T. Willemsen, A. Wiersma, E. J. Franssen, F. G. Russel, J. Korf, A. M. Paans. Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J. Nucl. Med. 1996, 37, 2082.
21. A. Taylor, V. Marks. Cobalt: A review. J. Hum. Nutr. 1978, 32, 165.
22. A. J. Seaman, R. D. Koler. Acquired erythrocytic hypoplasia: A recovery during cobalt therapy; report of two cases with review of the literature. Acta Haematol. 1953, 9, 153.
23. M. A. Voyce. A case of pure red-cell aplasia successfully treated with cobalt. Brit. J. Haematol. 1963, 9, 412.
24. J. R. Fountain, M. Dales. Pure redcell aplasia successfully treated with cobalt. Lancet 1955, 268, 541.
25. A. Licht, M. Oliver, E. A. Rachmilewitz. Optic atrophy following treatment with cobalt chloride in a patient with pancytopenia and hypercellular marrow. Isr. J. Med. Sci. 1972, 8, 61.
26. J. Wolf, I. J. Levy. Treatment of sickle cell anemia with cobalt chloride. AMA Arch. Intern. Med. 1954, 93, 387.
27. J. P. Kriss, W. H. Carnes, R. T. Gross. Hypothyroidism and thyroid hyperplasia in patients treated with cobalt. J. Am. Med. Assoc. 1955, 157, 117.
28. P. P. Weinsaft, L. H. Bernstein. Cobaltous chloride in the treatment of certain refractory anemias. Am. J. Med. Sci. 1955, 230, 264.
29. F. H. Gardner. The use of cobaltous chloride in the anemia associated with chronic renal disease. J. Lab. Clin. Med. 1953, 41, 56.
30. P. Schleisner. Cobalt in anaemia. Acta Med. Scand. 1956, 154, 177.
31. A. Kasanen, M. Kulonen, J. Forsstrom. Oral cobalt therapy in renal anemia. Ann. Med. Intern. Fenn. 1963, 52, 43.
32. T. Geill. On the treatment of the nephrogenic anaemias with a combined cobalt-iron preparation. Gerontol. Clin. 1969, 11, 48.
33. M. S. Edwards, J. R. Curtis. Use of cobaltous chloride in anaemia of maintenance hemodialysis patients. Lancet 1971, 2, 582.
34. E. A. Bowie, P. J. Hurley. Cobalt chloride in the treatment of refractory anaemia in patients undergoing long-term haemodialysis. Aust. N.Z. J. Med. 1975, 5, 306.
35. J. R. Curtis, G. C. Goode, J. Herrington, L. E. Urdaneta. Possible cobalt toxicity in maintenance hemodialysis patients after treatment with cobaltous chloride: A study of blood and tissue cobalt concentrations in normal subjects and patients with terminal and renal failure. Clin. Nephrol. 1976, 5, 61.
36. J. M. Duckham, H. A. Lee. The treatment of refractory anaemia of chronic renal failure with cobalt chloride. Q. J. Med. 1976, 45, 277.
37. I. H. Manifold, M. M. Platts, A. Kennedy. Cobalt cardiomyopathy in a patient on maintenance haemodialysis. Brit. Med. J. 1978, 2, 1609.
38. L. Weissbecker. Neue Möglichkeiten der Kobalttherapie. Klin. Wochenschr. 1951, 29, 80.
39. D. G. Barceloux. Cobalt. J. Toxicol. Clin. Toxicol. 1999, 37, 201.
40. A. Oller, H. Bates. Metals in perspective: Introduction. J. Environ. Monitor. 2004, 6, 145.
41. L. O. Simonsen, H. Harbak, P. Bennekou. Cobalt metabolism and toxicology-A brief update. Sci. Total Environ. 2012, 432, 210.
42. S. Bradberry, M. Sabatta, J. Vale. Cobalt Chloride. Available at: www.inchem.org/documents/ukpids/ukpids/ukpid50.htm Access date: [16 August 2013].
43. B. L. Finley, A.D. Monnot, D.J. Paustenbach, S.H. Gaffney. Derivation of a chronic oral reference dose for cobalt. Regul. Toxicol. Pharm. 2012, 64, 491.
44. E. S. Mucklow, S. J. Griffin, H. T. Delves, B. Suchak. Cobalt poisoning in a 6-year-old. Lancet 1990, 335, 981.
45. H. Jacobziner, H. W. Raybin. Poison control accidental cobalt poisoning. Arch. Pediatr. 1961, 78, 200.
46. U. O. Schirrmacher. Case of cobalt poisoning. Brit. Med. J. 1967, 1, 544.
47. L. Berk, J. H. Burchenal, T. Wood, W.B. Castle. Oxygen saturation of sternal marrow blood with special reference to pathogenesis of polycythemia vera. Proc. Soc. Exp. Biol. Med. 1948, 69, 316.
48. K. R. Paley, E. S. Sobel, R. S. Yalow. Effect of oral and intravenous cobaltous chloride on thyroid function. J. Clin. Endocr. Metab. 1958, 18, 850.
49. J. C. Weaver, V. M. Kostainsek, D. N. Richards Jr. Cobalt tumor of the thyroid gland. Calif. Med. 1956, 85, 110.
50. P. Seghizzi, F. D'Adda, D. Borleri, F. Barbic, G. Mosconi. Cobalt myocardiopathy. A critical review of literature. Sci. Total Environ. 1994, 150, 105.
51. Y. Morin, A. Tetu, G. Mercier. Cobalt cardiomyopathy: Clinical aspects. Brit. Heart J. 1971, 33(8), 175.
52. C. S. Alexander. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. Am. J. Med. 1972, 53, 395.
53. D. Lison. Human toxicity of cobalt-containing dust and experimental studies on the mechanism of interstitial lung disease (hard metal disease). Crit. Rev. Toxicol. 1996, 26, 585.
54. R. Krapf, H. N. Hulter. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin. J. Am. Soc. Nephrol. 2009, 4, 470.
55. W. Jelkmann, S. Elliott. Erythropoietin and the vascular wall: The controversy continues. Nutr. Metab. Cardiovasc. Dis. 2012 [Epub ahead of print]. PMID: 22682530.
56. N. T. Shahidi. Androgens and erythropoiesis. New Engl. J. Med. 1973, 289, 72.
57. K. Kanaya, T. Kamitani. pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. Biochem. Biophys. Res. Commun. 2003, 306, 750.
58. Y. Yuan, D. Beitner-Johnson, D. E. Millhorn. Hypoxia-inducible factor 2alpha binds to cobalt in vitro. Biochem. Biophys. Res. Commun. 2001, 288, 849.
59. Y. Yuan, G. Hilliard, T. Ferguson, D. E. Millhorn. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem. 2003, 278, 15911.
60. S. Nagel, N. P. Talbot, J. Mecinovic, T. G. Smith, A. M. Buchan, C. J. Schofield. Therapeutic manipulation of the HIF hydroxylases. Antioxid. Redox Signal. 2010, 12, 481.
61. M. De Boeck, M. Kirsch-Volders, D. Lison. Cobalt and antimony: Genotoxicity and carcinogenicity. Mutat. Res. 2003, 533, 135.
62. D. Beyersmann, A. Hartwig. The genetic toxicology of cobalt. Toxicol. Appl. Pharmacol. 1992, 115, 137.
63. J. Suzuki. Time-course changes in VEGF expression and capillarity in the early stage of exercise training with Co treatment in rat skeletal muscles. Acta Physiol. Scand. 2004, 181, 225.
64. D. Shukla, S. Saxena, J. Purushothaman, K. Shrivastava, M. Singh, S. Shukla, V. K. Malhotra, S. Mustoori, A. Bansal. Hypoxic preconditioning with cobalt ameliorates hypobaric hypoxia induced pulmonary edema in rat. Eur. J. Pharmacol. 2011, 656, 101.
65. S. Saxena, D. Shukla, A. Bansal. Augmentation of aerobic respiration and mitochondrial biogenesis in skeletal muscle by hypoxia preconditioning with cobalt chloride. Toxicol. Appl. Pharmacol. 2012, 264, 324.
66. L. O. Simonsen, A. M. Brown, H. Harbak, B. I. Kristensen, P. Bennekou. Cobalt uptake and binding in human red blood cells. Blood Cell Mol. Dis. 2011, 46, 266.
67. K. M. Unice, A. D. Monnot, S. H. Gaffney, B. E. Tvermoes, K. A. Thuett, D. J. Paustenbach, B. L. Finley. Inorganic cobalt supplementation: Prediction of cobalt levels in whole blood and urine using a biokinetic model. Food Chem. Toxicol. 2012, 50, 2456.